Get 25% discount on our yearly plans! Subscribe now
| Market Cap | |
| Total Shares Outstanding | |
| Book Value | |
| PE Ratio |
| PS Ratio | |
| PB Ratio | |
| Forward PE Ratio | |
| ROIC |
| Return on Aseets | |
| Return on Equity | |
| Dividend | |
| Dividend Yield |
| Total Assets | 30.45M |
| Total Liability | 26.04M |
| Assets-to-Libability Ratio | 1.17 |
| Total Current Assets | 3.93M |
| Total Current Liability | 14.43M |
| Current Ratio | 0.27 |
| Quick Ratio | - |
| Debt to Equity Ratio | - |
| Net Income | -67.64M |
| EPS | -19.03 |
| EBITA | -32.49M |
| Gross Profit | - |
| Gross Profit Margin | - |
| Operating Margin | - |
| Net Profit Margin | - |
| 5 Days MA | |
| 10 Days MA | |
| 20 Days MA | |
| 50 Days MA | |
| 200 Days MA |
| 52 Weeks High | |
| 52 Weeks low | |
| All Time High |
| RSI | |
| MACD |
| Shares Float | |
| Shares Short |
| % Short | |
| % Insider |
| % Institutions |
Windtree Therapeutics Inc (WINT)
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Exchange: NASDAQ
IPO Date: 8/8/1995
Sector: Healthcare
Industry: Biotechnology
Employees: 0
Address: 2600 Kelly Road, Warrington, PA, United States, 18976-3622
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | Totals | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 30.45K | 28.71K | 30.10K | 32.41K | 36.06K | 40.58K | 35.19K | 37.95K | 48.10K | 51.81K | 2.40M | ||||||||||||||||||||||||||||||||||
| Current Assets | 3.93K | 2.06K | 3.34K | 5.38K | 8.91K | 13.32K | 5.22K | 7.38K | 10.03K | 13.16K | 894.68K | ||||||||||||||||||||||||||||||||||
| Cash And Short Term Investments | 2.30K | 1.80K | 2.55K | 4.32K | 7.37K | 11.47K | 4.24K | 6.17K | 8.44K | 11.38K | 829.87K | ||||||||||||||||||||||||||||||||||
| Net Receivables | - | - | - | - | - | - | - | - | - | - | 241 | ||||||||||||||||||||||||||||||||||
| Inventory | - | - | - | - | - | - | - | - | - | - | 1.03K | ||||||||||||||||||||||||||||||||||
| Other Current Assets | 1.63K | 256 | 792 | 1.06K | 1.54K | 1.85K | 987 | 1.21K | 1.60K | 1.78K | 413.54K | ||||||||||||||||||||||||||||||||||
| Non Current Assets | 26.52K | 26.65K | 26.76K | 27.03K | 27.15K | 27.26K | 29.96K | 30.58K | 38.07K | 38.65K | 1.43M | ||||||||||||||||||||||||||||||||||
| Property Plant Equipment | - | - | - | - | - | - | - | - | 2.25K | 2.38K | 50.80K | ||||||||||||||||||||||||||||||||||
| Long Term Investments | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Non Currrent Assets Other | 9 | 9 | 9 | 150 | 150 | 150 | 163 | 154 | 154 | 154 | -55.09K | ||||||||||||||||||||||||||||||||||
| Liabilities | 26.04K | 18.26K | 14.68K | 29.02K | 28.57K | 28.97K | 28.16K | 27.94K | 30.68K | 32.62K | 1.50M | ||||||||||||||||||||||||||||||||||
| Current Liabilities | 14.43K | 8.78K | 4.99K | 4.00K | 3.71K | 3.79K | 2.76K | 2.46K | 3.95K | 5.33K | 467.80K | ||||||||||||||||||||||||||||||||||
| Accounts Payable | 2.05K | 2.97K | 1.69K | 809 | 944 | 964 | 753 | 249 | 410 | 1.07K | 314.61K | ||||||||||||||||||||||||||||||||||
| Short Long Term Debt | 761 | 2.01K | - | 233 | 467 | 700 | - | 252 | 629 | 1.01K | 170.00K | ||||||||||||||||||||||||||||||||||
| Other Current Liabilities | 11.90K | 3.34K | 2.85K | 2.52K | 1.86K | 2.43K | 1.62K | 1.55K | 2.50K | 2.82K | 338.89K | ||||||||||||||||||||||||||||||||||
| Non Current Liabilities | 11.61K | 9.48K | 9.70K | 25.02K | 24.86K | 25.18K | 25.39K | 25.48K | 26.73K | 27.28K | 1.00M | ||||||||||||||||||||||||||||||||||
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 304.60K | ||||||||||||||||||||||||||||||||||
| Other Liabilities | - | - | - | - | - | - | - | - | 9.99K | 10.44K | 238.04K | ||||||||||||||||||||||||||||||||||
| Stockholder Equity | 4.41K | 10.45K | 15.42K | 3.39K | 7.48K | 11.60K | 7.03K | 10.01K | 17.42K | 19.20K | 885.76K | ||||||||||||||||||||||||||||||||||
| Preferred Stock Equity | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Liabilities And Stockholders Equity | 30.45K | 28.71K | 30.10K | 32.41K | 36.06K | 40.58K | 35.19K | 37.95K | 48.10K | 51.81K | 2.40M | ||||||||||||||||||||||||||||||||||
| Common Equity | - | - | - | - | - | - | - | - | - | - | 1.11K | ||||||||||||||||||||||||||||||||||
| Retained Earnings | - | - | - | - | - | - | - | - | - | - | -18.83M | ||||||||||||||||||||||||||||||||||
| Totals | 166.49K | 143.47K | 142.98K | 167.73K | 185.13K | 208.84K | 176.66K | 189.34K | 249.04K | 270.91K | 335.13K | 374.41K | 420.94K | -314.14K | -71.70K | -175.36K | -139.63K | -82.90K | -36.19K | -97.08K | -79.86K | -36.24K | -59.76K | -73.80K | -577.44K | -558.84K | -555.61K | -565.85K | -533.90K | -515.77K | -489.71K | -468.24K | -451.14K | -398.22K | -330.93K | -274.82K | -228.95K | -337.13K | -277.65K | -230.66K | -166.22K | -97.14K | -36.30K | -5.23M | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | Totals | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 32.41K | 37.95K | 74.79K | 112.89K | 118.97K | 119.40K | 3.35K | 9.70K | 44.38K | 47.50K | 601.33K | |
| Current Assets | 5.38K | 7.38K | 23.49K | 18.12K | 23.86K | 25.65K | 2.24K | 7.19K | 40.79K | 45.56K | 199.66K | |
| Cash And Short Term Investments | 4.32K | 6.17K | 22.35K | 16.93K | 22.58K | 25.15K | 1.81K | 5.59K | 38.95K | 44.94K | 188.78K | |
| Net Receivables | - | - | - | - | - | - | - | - | - | 78 | 78 | |
| Inventory | - | - | - | - | - | - | - | - | - | 27 | 27 | |
| Other Current Assets | 1.06K | 1.21K | 2.29K | 2.38K | 1.28K | 507 | 422 | 1.61K | 4.39K | 821 | 15.96K | |
| Non Current Assets | 27.03K | 30.58K | 51.30K | 94.77K | 95.11K | 93.75K | 1.11K | 2.50K | 3.58K | 1.94K | 401.67K | |
| Property Plant Equipment | - | - | 3.39K | 1.84K | 798 | 802 | 885 | 1.05K | 1.04K | 1.64K | 11.45K | |
| Long Term Investments | - | - | - | - | - | - | - | - | - | - | - | |
| Non Currrent Assets Other | 150 | 154 | 154 | 154 | 154 | 171 | 225 | 1.45K | 2.54K | 303 | 5.46K | |
| Liabilities | 29.02K | 27.94K | 32.91K | 43.33K | 44.04K | 51.28K | 27.27K | 38.53K | 36.11K | 28.30K | 358.73K | |
| Current Liabilities | 4.00K | 2.46K | 4.92K | 6.13K | 7.82K | 20.63K | 11.76K | 13.39K | 11.07K | 7.83K | 90.00K | |
| Accounts Payable | 809 | 249 | 693 | 1.16K | 1.71K | 3.42K | 3.05K | 9.42K | 10.89K | 6.63K | 38.03K | |
| Short Long Term Debt | 233 | 252 | 294 | 352 | 161 | 7.97K | 15.00K | 25.00K | 25.00K | 62 | 74.33K | |
| Other Current Liabilities | 2.52K | 1.15K | 2.88K | 3.01K | 5.20K | 9.04K | 7.83K | 3.97K | 3.50K | 43 | 39.13K | |
| Non Current Liabilities | 25.02K | 25.48K | 27.98K | 37.20K | 36.22K | 30.65K | 15.51K | 25.14K | 25.04K | 20.47K | 268.72K | |
| Long Term Debt | - | - | - | 2.42K | 19.61K | 15.00K | 15.00K | 25.00K | 25.00K | 20.30K | 122.33K | |
| Other Liabilities | - | - | 10.91K | 19.58K | 15.82K | 15.65K | 507 | 138 | 43 | 169 | 62.82K | |
| Stockholder Equity | 3.39K | 10.01K | 41.88K | 69.55K | 74.94K | 68.11K | -23.92K | -28.83K | 8.27K | 19.20K | 242.60K | |
| Preferred Stock Equity | - | - | - | - | - | - | - | - | - | - | - | |
| Liabilities And Stockholders Equity | 32.41K | 37.95K | 74.79K | 112.89K | 118.97K | 119.40K | 3.35K | 9.70K | 44.38K | 47.50K | 601.33K | |
| Common Equity | - | - | - | 17 | 41 | 32 | 3 | 9 | 8 | 86 | 196 | |
| Retained Earnings | - | - | - | -717.69K | -685.12K | -657.65K | -637.11K | -618.67K | -579.18K | -524.01K | -4.42M | |
| Totals | 167.73K | 188.94K | 375.02K | -174.97K | -97.83K | -51.03K | -551.73K | -468.11K | -254.19K | -230.61K | -1.10M | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | 03/31/2020 | Totals | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 9.52K | |||||||||||||||||||||||||
| Cost Of Revenue | - | - | - | - | - | - | - | - | - | - | 114.48K | |||||||||||||||||||||||||
| Gross Profit | - | - | - | - | - | - | - | - | - | - | 582 | |||||||||||||||||||||||||
| Operating Expenses | 5.90K | 8.33K | 7.44K | 8.15K | 7.59K | 9.08K | 6.96K | 8.71K | 7.95K | 4.55K | 262.18K | |||||||||||||||||||||||||
| Selling General Administrative | 2.91K | 2.99K | 2.97K | 3.47K | 3.37K | 4.67K | 3.43K | 4.82K | 3.45K | 2.41K | 92.12K | |||||||||||||||||||||||||
| Research Development | 3.00K | 5.34K | 4.48K | 4.68K | 4.22K | 4.41K | 3.54K | 3.88K | 4.50K | 2.14K | 170.84K | |||||||||||||||||||||||||
| Other Operating Expenses | 5.90K | 8.33K | 7.44K | 8.15K | 7.59K | 9.08K | 6.96K | 8.71K | 7.95K | 6.35K | 276.17K | |||||||||||||||||||||||||
| Operating Income | -17.54K | -8.33K | -14.69K | -8.15K | -45.36K | -9.08K | -6.96K | -8.71K | -7.95K | -6.35K | -323.31K | |||||||||||||||||||||||||
| Net Interest Income | 4 | -12 | -12 | -13 | -7 | 9 | 3 | -25 | -26 | 45 | -376 | |||||||||||||||||||||||||
| Interest Income | 17 | 1 | 1 | 1 | 39 | 50 | 7 | 21 | 5 | 89 | 248 | |||||||||||||||||||||||||
| Interest Expense | 13 | 13 | 13 | 14 | 46 | 41 | 4 | 46 | 31 | 137 | 16.33K | |||||||||||||||||||||||||
| Other Income Expense Net | 205 | 206 | -36 | -66 | -359 | 118 | -493 | 315 | 1.61K | 1.03K | 10.41K | |||||||||||||||||||||||||
| Income Before Tax | -17.33K | -8.13K | -14.73K | -8.21K | -45.72K | -8.96K | -7.45K | -9.02K | -9.56K | -7.38K | -337.18K | |||||||||||||||||||||||||
| Tax Provision | - | - | -1.66K | - | -8.33K | - | - | - | - | - | -9.99K | |||||||||||||||||||||||||
| NetIncome | -17.33K | -8.13K | -13.07K | -8.21K | -37.39K | -8.96K | -7.45K | -9.02K | -9.56K | -7.38K | -327.19K | |||||||||||||||||||||||||
| NetIncome Applicable To Common Shares | -17.33K | -8.13K | -13.07K | -8.21K | -37.39K | -8.96K | -7.45K | -9.02K | -9.56K | -6.53K | -351.43K | |||||||||||||||||||||||||
| Ebit | -5.68K | -8.11K | -7.46K | -8.20K | -7.91K | -8.92K | -7.45K | -8.97K | -7.95K | -6.35K | -267.21K | |||||||||||||||||||||||||
| Basic EPS | - | -0.29 | -0.52 | -0.31 | -1.42 | -0.51 | -0.43 | -0.54 | -0.63 | -0.48 | -408.24999999999994 | |||||||||||||||||||||||||
| Totals | -57.28K | -15.62K | -42.39K | -16.61K | -159.60K | -17.43K | -16.37K | -18.27K | -19.11K | -17.23K | -20.23K | -14.20K | -8.59K | -17.06K | -37.65K | -4.06K | 2.11K | 13.32K | 19.61K | -7.52K | -488.6 | -10.48K | -927.2 | -2.70K | -10.45K | -14.04K | -5.97K | -56.35K | -10.65K | -24.06K | -15.98K | -19.36K | -16.13K | -22.48K | -664.22K | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | Totals | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 198 | 1.79K | 1.49K | 2.04K | 987 | 2.83K | 9.34K | |
| Cost Of Revenue | - | - | - | 10.56K | 17.38K | - | 929 | 1.85K | 30.72K | |
| Gross Profit | - | - | 198 | -8.77K | 1.49K | 2.04K | 58 | 5.67K | 679 | |
| Operating Expenses | 32.26K | 30.32K | 25.09K | 17.98K | 24.03K | 40.08K | 39.89K | 43.42K | 253.08K | |
| Selling General Administrative | 14.47K | 14.94K | 12.40K | 7.42K | 6.66K | 8.37K | 11.00K | 16.73K | 92.01K | |
| Research Development | 17.79K | 15.37K | 12.69K | 10.56K | 17.38K | 31.70K | 28.89K | 26.69K | 161.07K | |
| Other Operating Expenses | 32.26K | 30.32K | 26.89K | 21.33K | 18.21K | 40.08K | 52.58K | 46.09K | 267.75K | |
| Operating Income | -77.28K | -30.32K | -24.89K | -16.20K | -22.55K | -38.04K | -51.59K | -43.26K | -304.12K | |
| Net Interest Income | -23 | -3 | -342 | -1.39K | -1.85K | -2.50K | - | - | -6.11K | |
| Interest Income | 91 | 122 | 153 | 15 | 12 | 18 | -3.73K | - | -3.32K | |
| Interest Expense | 114 | 125 | 495 | 1.41K | 1.86K | 2.52K | 4.67K | 4.60K | 15.79K | |
| Other Income Expense Net | -343 | -2.25K | -2.58K | -4.34K | 4.10K | 1.45K | 3.58K | 800 | 422 | |
| Income Before Tax | -77.62K | -32.57K | -27.48K | -20.53K | -18.45K | -39.49K | -55.17K | -44.06K | -315.36K | |
| Tax Provision | -9.99K | - | - | - | - | - | - | - | -9.99K | |
| NetIncome | -67.64K | -32.57K | -27.48K | -20.53K | -18.45K | -39.49K | -55.17K | -44.06K | -305.37K | |
| NetIncome Applicable To Common Shares | -67.64K | -32.57K | -27.48K | -34.76K | -24.82K | -39.49K | -55.17K | -44.06K | -325.97K | |
| Ebit | -32.49K | -32.44K | -26.98K | -19.12K | -16.58K | -38.04K | -51.59K | -43.26K | -260.50K | |
| Basic EPS | -2.76 | -2.7 | - | -19.47 | -166.72 | -133.7 | -6.3 | -76.3 | -407.95000000000005 | |
| Totals | -236.03K | -71.51K | -59.11K | -54.60K | -10.26K | -68.87K | -129.85K | -70.07K | -700.30K | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | Totals | ||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash From Operating Activities | -6.44K | -2.33K | -2.95K | -3.57K | -3.85K | -3.50K | -2.52K | -3.38K | -4.10K | -5.26K | -263.01K | ||||||||||||||||||||||||||||||||||
| Net Income | -2.75K | -12.02K | 10.22K | -5.15K | -4.42K | -6.60K | -4.11K | -9.69K | -4.06K | -17.33K | -365.79K | ||||||||||||||||||||||||||||||||||
| Depreciation | 127 | 229 | 21 | 22 | 14 | 23 | 23 | 24 | 21 | 22 | 3.65K | ||||||||||||||||||||||||||||||||||
| Extraordinary Items | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||
| Change Receivables | - | - | - | - | - | - | - | - | - | - | 67 | ||||||||||||||||||||||||||||||||||
| Change To Inventory | - | - | - | - | - | - | - | - | - | - | -984 | ||||||||||||||||||||||||||||||||||
| Change To Liabilities | - | - | - | - | - | - | 504 | - | -662 | 348 | 3.92K | ||||||||||||||||||||||||||||||||||
| Change To Net Income | - | - | - | - | - | - | 906 | - | 452 | 11.92K | 88.83K | ||||||||||||||||||||||||||||||||||
| ChangeToOperatingActivities | - | - | - | - | - | - | 159 | - | -254 | -615 | -8.24K | ||||||||||||||||||||||||||||||||||
| Cash flows From Investing Activities | - | - | - | - | - | - | - | - | - | 200 | -15.27K | ||||||||||||||||||||||||||||||||||
| Capital Expenditures | - | -12 | - | - | -15 | - | - | - | -13 | -10 | -3.48K | ||||||||||||||||||||||||||||||||||
| Other Cashflows From Investing Activities | - | - | - | - | - | - | - | - | - | - | 40.49K | ||||||||||||||||||||||||||||||||||
| Cash From Financing Activities | 6.94K | 1.59K | 1.03K | 521 | -233 | 10.72K | 591 | 1.12K | 1.16K | 895 | 264.18K | ||||||||||||||||||||||||||||||||||
| Net Borrowings | - | - | - | - | - | - | -252 | - | -378 | -125 | 1.45K | ||||||||||||||||||||||||||||||||||
| Sale Purchase Of Stock | - | - | - | - | - | - | - | - | - | - | 132.08K | ||||||||||||||||||||||||||||||||||
| Dividends Paid | -347 | - | - | - | - | - | - | - | - | - | -347 | ||||||||||||||||||||||||||||||||||
| Other Cashflows From Financing Activities | -747 | -68 | -333 | -234 | -15 | - | 0.591 | - | 1.96K | 200 | 207.54K | ||||||||||||||||||||||||||||||||||
| Cash And Cash Equivalents Changes | - | - | - | - | - | - | - | - | - | - | -62.97K | ||||||||||||||||||||||||||||||||||
| Totals | -3.22K | -12.61K | 7.99K | -8.41K | -8.53K | 641 | -4.70K | -11.93K | -5.87K | -9.76K | -13.42K | -7.54K | -10.85K | -25.57K | 64.25K | -35.18K | -27.39K | 40.91K | 28.44K | 106.34K | 9.34K | 23.07K | 33.55K | 86.33K | -10.52K | 2.65K | 14.27K | 5.04K | 5.31K | -14.03K | 8.52K | -23.95K | -24.90K | -27.79K | 1.03K | -3.30K | 59.19K | -28.68K | -28.63K | -31.21K | -32.92K | -32.65K | -31.19K | 22.13K | |
| &ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp;&ebsp; | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | Totals | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash From Operating Activities | -13.44K | -19.45K | -23.66K | -25.32K | -24.66K | -15.78K | -21.05K | -33.59K | -33.50K | -41.17K | -251.62K | |
| Net Income | -20.29K | -39.21K | -67.64K | -32.57K | -27.48K | -20.53K | -18.45K | -39.49K | -55.17K | -44.06K | -364.87K | |
| Depreciation | 82 | 533 | 192 | 165 | 195 | 159 | 192 | 255 | 712 | 818 | 3.30K | |
| Extraordinary Items | - | - | - | - | - | - | - | - | - | - | - | |
| Change Receivables | - | - | - | - | - | - | - | - | - | 67 | 67 | |
| Change To Inventory | - | - | - | - | - | - | - | - | 201 | -1.79K | -1.59K | |
| Change To Liabilities | - | - | -468 | -547 | -5.65K | 739 | -572 | 1.44K | 4.21K | -217 | -1.06K | |
| Change To Net Income | - | - | 43.84K | 8.41K | 8.44K | 4.29K | -4.17K | -223 | 13.05K | 2.00K | 75.64K | |
| ChangeToOperatingActivities | - | - | 410 | -781 | -4.24K | -466 | -3.26K | 1.05K | 4.76K | 918 | -1.61K | |
| Cash flows From Investing Activities | - | - | -279 | -291 | 13.80K | -13.73K | -24 | -254 | -188 | -780 | -1.75K | |
| Capital Expenditures | -15 | -13 | -279 | -291 | -191 | -9 | -24 | -281 | -458 | -780 | -2.34K | |
| Other Cashflows From Investing Activities | - | - | - | - | 13.99K | 232 | - | 27 | 270 | 270 | 14.79K | |
| Cash From Financing Activities | 11.60K | 3.08K | 29.36K | 19.96K | 21.77K | 38.74K | 17.30K | 709 | 27.70K | 377 | 170.58K | |
| Net Borrowings | - | - | -3.87K | -3.23K | -1.06K | 6.00K | 1.40K | 1.40K | -5.06K | -80 | -4.51K | |
| Sale Purchase Of Stock | - | - | - | 20.39K | 22.98K | 32.89K | 1.04K | 709 | 32.77K | 457 | 111.23K | |
| Dividends Paid | - | - | - | - | - | - | - | - | - | - | - | |
| Other Cashflows From Financing Activities | 843 | 197 | 29.36K | 2.94K | 849 | 7.50K | 17.72K | -254 | -198 | -457 | 58.51K | |
| Cash And Cash Equivalents Changes | - | - | - | -5.65K | 11.37K | 9.32K | -3.77K | -39.71K | -5.99K | -41.57K | -76.00K | |
| Totals | -21.22K | -54.86K | 6.96K | -16.81K | 30.11K | 49.36K | -13.66K | -108.21K | -16.90K | -125.99K | -271.22K | |
